Patent Assignment
Reel/Frame 064207/0957
Security Interest
Recorded: 2023-07-06
Pages: 16
Assignee
FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT
505 HOWARD STREET, FLOOR 3, SAN FRANCISCO, CALIFORNIA, 94105
Covered Properties
(134)
Carboxamides as Ubiquitin-Specific Protease Inhibitors
PCT:
PCT/US2019/045732 ↗
Inhibiting Deubiquitinase USP25 and USP28
PCT:
PCT/US2019/045734 ↗
BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER
PCT:
PCT/US2020/018680 ↗
Inhibiting USP36
PCT:
PCT/US2020/030833 ↗
Inhibiting Trabid
PCT:
PCT/US2020/031214 ↗
Inhibiting USP19
PCT:
PCT/US2020/031608 ↗
Integrated System for 3D Tissue Culture
PCT:
PCT/US2021/016317 ↗
Method and Apparatus for Molecular Mechanics Analysis of Molecular Systems
Molecular Property Modeling Using Ranking
Estimating the Accuracy of Molecular Property Models and Predictions
Modeling Biological Effects of Molecules Using Molecular Property Models
Derivatives of Squaric Acid with Anti-Proliferative Activity
Pyrido [2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
Raf Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Novel Compounds and Compositions for the Inhibition of Nampt
Piperidine Derivatives and Compositions for the Inhibition of Nicotinamide Phosphoribosyltransferase (Nampt)
Pyridinyl and Pyrimidinyl Sulfoxide and Sulfone Derivatives
Amido-Benzyl Sulfone and Sulfoxide Derivatives
Amido Spirocyclic Amide and Sulfonamide Derivatives
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
3-Spirocyclic-6-Hydroxamic Acid Tetralins as Hdac Inhibitors
3-Spiro-7-Hydroxamic Acid Tetralins as Hdac Inhibitors
[6,6] Fused Bicyclic HDAC8 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Amido Spirocyclic Amide and Sulfonamide Derivatives
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
[6,6] Fused Bicyclic HDAC8 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Thienopyrazine Carboxamides as Ubiquitin-Specific Protease Inhibitors
Thienopyridine Carboxamides as Ubiquitin-Specific Protease Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
Methods Using HDAC11 Inhibitors
Methods Using HDAC11 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
2-Spiro-5- and 6-Hydroxamic Acid Indanes as Hdac Inhibitors
Monocyclic Compounds Useful as GPR120 Modulators
Bicyclic Compounds Useful as GPR120 Modulators
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
[6,6] Fused Bicyclic HDAC8 Inhibitors
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Methods Using HDAC11 Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
2-Spiro-5- and 6-Hydroxamic Acid Indanes as Hdac Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Amido Spirocyclic Amide and Sulfonamide Derivatives
Artificial Skeletal Muscle Tissue
Application:
16/952,267 →
Publication:
US 2023/0143572
Monocyclic Compounds Useful as GPR120 Modulators
Thienopyrazine Carboxamides as Ubiquitin-Specific Protease Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Piperidine Derivatives and Compositions for the Inhibition of Nicotinamide Phosphoribosyltransferase (Nampt)
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Isoindolines as Hdac Inhibitors
[6,6] Fused Bicyclic HDAC8 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Bicyclic Compounds Useful as GPR120 Modulators
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
2-Spiro-5- and 6-Hydroxamic Acid Indanes as Hdac Inhibitors
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Application:
17/161,324 →
Publication:
US 2021/0292337
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Application:
17/179,046 →
Publication:
US 2021/0323978
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Methods Using HDAC11 Inhibitors
Piperidine Derivatives and Compositions for the Inhibition of Nicotinamide Phosphoribosyltransferase (Nampt)
Application:
17/941,061 →
Publication:
US 2023/0110003
Monocyclic Compounds Useful as GPR120 Modulators
Isoindolines as Hdac Inhibitors
Application:
17/984,065 →
Publication:
US 2023/0242512
Novel Compounds and Compositions for the Inhibition of Nampt
[6,6] Fused Bicyclic HDAC8 Inhibitors
Application:
18/096,712 →
Publication:
US 2023/0406830
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
Tricyclic Phthalazinone Parp Inhibitors and Methods of Use
Application:
63/350,366 →
Process for Preparing 6-Substituted-1-(2H)-Isoquinolinones and Intermediate Compound
Application:
63/394,110 →
Biomarker Combinations for Prognosis and Management of Diabetic Retinopathy
Application:
63/401,465 →
System and Method for Predicting and Optimizing Clinical Trial Outcomes
Application:
63/429,775 →
Spectral Encoding of Tissue Behavior
Application:
63/429,797 →
Systems and Methods for Processing of Functional Response Waveforms
Application:
63/457,574 →
Systems and Methods for Detecting Spontaneous Tissue Contractions
Application:
63/466,105 →
Invertible Models of Cardiac Function
Application:
63/482,630 →
Selective Fiasma Treatment
Application:
63/482,827 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jul 3, 2003
From: BENNETT, FORREST H., III; MYDLOWEC, WILLIAM
To: PHARMIX CORPORATION
Reel/Frame 014246/0349 →
Assignment of Assignor's Interest
Mar 29, 2006
From: LANZA, GUIDO; DUFFY, NIGEL P.; BOARDMAN, PAUL
To: PHARMIX CORPORATION
Reel/Frame 017395/0376 →
Assignment of Assignor's Interest
Nov 17, 2006
From: DUFFY, NIGEL P.
To: PHARMIX CORPORATION
Reel/Frame 018540/0648 →
Assignment of Assignor's Interest
Nov 17, 2006
From: DUFFY, NIGEL P.; LANZA, GUIDO; YU, JESSEN
To: PHARMIX CORPORATION
Reel/Frame 018540/0635 →
Assignment of Assignor's Interest
Sep 25, 2007
From: MURTHI, KRISHNA K.; KOSTLER, ROLAND; SMITH, CHASE; BRANDSTETTER, TILMANN
To: GPC BIOTECH AG
Reel/Frame 019878/0970 →
Assignment of Assignor's Interest
Oct 26, 2007
From: PHARMIX CORPORATION
To: NUMERATE, INC.
Reel/Frame 020037/0962 →
Assignment of Assignor's Interest
Nov 2, 2007
From: PHARMIX CORPORATION
To: NUMERATE, INC.
Reel/Frame 020063/0499 →
Assignment of Assignor's Interest
Nov 2, 2007
From: PHARMIX CORPORATION
To: NUMERATE, INC.
Reel/Frame 020061/0925 →
Assignment of Assignor's Interest
Sep 28, 2009
From: GPC BIOTECH AG; GPC BIOTECH, INC.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 023298/0850 →
Assignment of Assignor's Interest
Sep 28, 2009
From: MURTHI, KRISHNA; CASAUBON, REBECCA; KLUGE, ARTHUR F.; SMITH, CHASE
To: GPC BIOTECH, INC.
Reel/Frame 023302/0017 →
Assignment of Assignor's Interest
Sep 28, 2009
From: GPC BIOTECH AG; GPC BIOTECH, INC.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 023301/0352 →
Assignment of Assignor's Interest
Feb 21, 2012
From: FORMA THERAPEUTICS, INC
To: FORMA TM LLC
Reel/Frame 027733/0930 →
Assignment of Assignor's Interest
Jun 19, 2012
From: GPC BIOTECH AG; GPC BIOTECH INC.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 028402/0804 →
Assignment of Assignor's Interest
Jun 19, 2012
From: MURTHI, KRISHNA; CASAUBON, REBECCA; KLUGE, ARTHUR F; SMITH, CHASE C
To: GPC BIOTECH AG; GPC BIOTECH INC
Reel/Frame 028402/0656 →
Assignment of Assignor's Interest
Jun 19, 2012
From: NEUMAN, LARS; EICKHOFF, JAN; HANNUS, STEFAN; SCHOOP, ANDREAS
To: GPC BIOTECH AG
Reel/Frame 028562/0384 →
Security Agreement
Feb 11, 2013
From: NUMERATE, INC.
To: LEADER VENTURES, LLC, AS AGENT
Reel/Frame 029793/0056 →
Assignment of Assignor's Interest
Mar 24, 2015
From: FORMA THERAPEUTICS, INC.
To: FORMA TM, LLC
Reel/Frame 035238/0913 →
Assignment of Assignor's Interest
Mar 24, 2015
From: PHARMARON, INC.
To: GENENTECH, INC.
Reel/Frame 035239/0201 →
Assignment of Assignor's Interest
Mar 24, 2015
From: PHARMARON BEIJING, CO., LTD.
To: PHARMARON, INC.
Reel/Frame 035239/0167 →
Assignment of Assignor's Interest
Mar 24, 2015
From: LIU, XIONGCAI; YUEN, PO-WAI; ZHANG, YAMIN
To: PHARMARON BEIJING, CO., LTD.
Reel/Frame 035239/0105 →
Assignment of Assignor's Interest
Mar 24, 2015
From: DRAGOVICH, PETER; PATEL, SNAHEL; ZAK, MARK; ZHAO, GUILING
To: GENENTECH, INC.
Reel/Frame 035239/0035 →
Assignment of Assignor's Interest
Mar 24, 2015
From: BAIR, KENNETH W.; BAUMEISTER, TIMM R.; ZHENG, XIAOZHANG
To: FORMA THERAPEUTICS, INC.
Reel/Frame 035238/0637 →
Assignment of Assignor's Interest
Jan 19, 2016
From: IOANNIDIS, STEPHANOS; TALBOT, ADAM CHARLES; FOLLOWS, BRUCE; BUCKMELTER, ALEXANDRE JOSEPH
To: FORMA THERAPEUTICS, INC.
Reel/Frame 037523/0395 →
Assignment of Assignor's Interest
Jan 19, 2016
From: IOANNIDIS, STEPHANOS; TALBOT, ADAM CHARLES; FOLLOWS, BRUCE; BUCKMELTER, ALEXANDRE JOSEPH
To: FORMA THERAPEUTICS, INC.
Reel/Frame 037523/0344 →
Assignment of Assignor's Interest
Dec 15, 2016
From: BAIR, KENNETH W; BAUMEISTER, TIMM R; BUCKMELTER, ALEX J; CLODFELTER, KARL H
To: FORMA THERAPEUTICS, INC.
Reel/Frame 040993/0159 →